Skip to main content

Advertisement

Log in

In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli

European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Beta-lactam antibiotics have been discussed as options for the treatment of infections caused by multiresistant extended-spectrum beta-lactamase (ESBL)-producing bacteria if the minimum inhibitory concentration (MIC) is low. The objective of this study was to investigate the in vitro activity of different beta-lactam antibiotics against CTX-M-producing Escherichia coli. A total of 198 isolates of E. coli with the ESBL phenotype were studied. Polymerase chain reaction (PCR) amplification of CTX-M genes and amplicon sequencing were performed. The MICs for amoxicillin–clavulanic acid, aztreonam, cefepime, cefotaxime, ceftazidime, ceftibuten, ertapenem, imipenem, mecillinam, meropenem, piperacillin–tazobactam, and temocillin were determined with the Etest. Susceptibility was defined according to the breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). MIC50 and MIC90 values were calculated. Isolates from CTX-M group 9 showed higher susceptibility to the beta-lactam antibiotics tested than isolates belonging to CTX-M group 1. More than 90% of the isolates belonging to CTX-M group 9 were susceptible to amoxicillin–clavulanic acid, ceftazidime, ceftibuten, piperacillin–tazobactam, and temocillin. The susceptibility was high to mecillinam, being 91%, regardless of the CTX-M group. All isolates were susceptible to imipenem and meropenem, and 99% to ertapenem. This study shows significant differences in susceptibility to different beta-lactam antibiotics among the CTX-M-producing E. coli isolates and a significant difference for many antibiotics tested between the CTX-M-producing groups 1 and 9. The good in vitro activity of other beta-lactam antibiotics compared to carbapenems indicate that clinical studies are warranted in order to examine the potential role of these beta-lactam antibiotics in the treatment of infections caused by multiresistant ESBL-producing E. coli.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alsterlund R, Carlsson B, Gezelius L et al (2009) Multiresistant CTX-M-15 ESBL-producing Escherichia coli in southern Sweden: description of an outbreak. Scand J Infect Dis 41(6–7):410–415

    Article  PubMed  CAS  Google Scholar 

  2. Fang H, Ataker F, Hedin G et al (2008) Molecular epidemiology of extended-spectrum beta-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J Clin Microbiol 46(2):707–712

    Article  PubMed  CAS  Google Scholar 

  3. Kjerulf A, Hansen DS, Sandvang D et al (2008) The prevalence of ESBL-producing E. coli and Klebsiella strains in the Copenhagen area of Denmark. APMIS 116(2):118–124

    Article  PubMed  CAS  Google Scholar 

  4. Lytsy B, Sandegren L, Tano E et al (2008) The first major extended-spectrum beta-lactamase outbreak in Scandinavia was caused by clonal spread of a multiresistant Klebsiella pneumoniae producing CTX-M-15. APMIS 116(4):302–308

    Article  PubMed  CAS  Google Scholar 

  5. Naseer U, Natås OB, Haldorsen BC et al (2007) Nosocomial outbreak of CTX-M-15-producing E. coli in Norway. APMIS 115(2):120–126

    Article  PubMed  CAS  Google Scholar 

  6. Nyberg SD, Osterblad M, Hakanen AJ et al (2007) Detection and molecular genetics of extended-spectrum beta-lactamases among cefuroxime-resistant Escherichia coli and Klebsiella spp. isolates from Finland, 2002–2004. Scand J Infect Dis 39(5):417–424

    Article  PubMed  CAS  Google Scholar 

  7. Jacoby G, Bush K.OXA-type β-lactamases. Available online at: http://www.lahey.org/Studies/other.asp#table1. Last date accessed 9 August 2010

  8. Bonnet R (2004) Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 48(1):1–14

    Article  PubMed  CAS  Google Scholar 

  9. European Antimicrobial Resistance Surveillance System (EARSS) (2005) EARSS manual 2005. Available online at: http://www1.szu.cz/cem/earss/docs/Earss_manual_2005.pdf. Last date accessed 2 February 2011

  10. European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2008) Expert rules in antimicrobial susceptibility testing. Available online at: http://www.srga.org/eucastwt/EUCAST%20Expert%20rules%20final%20April_20080407.pdf. Last date accessed 9 August 2010

  11. European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2008) Expert rules. Home page at: http://www.eucast.org/expert_rules/. Last date accessed 9 August 2010

  12. Melzer M, Petersen I (2007) Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 55(3):254–259

    Article  PubMed  Google Scholar 

  13. Schwaber MJ, Carmeli Y (2007) Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 60(5):913–920

    Article  PubMed  CAS  Google Scholar 

  14. Cordery RJ, Roberts CH, Cooper SJ et al (2008) Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome. J Hosp Infect 68(2):108–115

    Article  PubMed  CAS  Google Scholar 

  15. Gudiol C, Calatayud L, Garcia-Vidal C et al (2010) Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 65(2):333–341

    Article  PubMed  CAS  Google Scholar 

  16. Ortega M, Marco F, Soriano A et al (2009) Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 63(3):568–574

    Article  PubMed  CAS  Google Scholar 

  17. Rodríguez-Baño J, Navarro MD, Romero L et al (2006) Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 43(11):1407–1414

    Article  PubMed  Google Scholar 

  18. Tumbarello M, Sanguinetti M, Montuori E et al (2007) Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 51(6):1987–1994

    Article  PubMed  CAS  Google Scholar 

  19. Tumbarello M, Sali M, Trecarichi EM et al (2008) Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 52(9):3244–3252

    Article  PubMed  CAS  Google Scholar 

  20. Song KH, Jeon JH, Park WB et al (2009) Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case–control study. BMC Infect Dis 9:41

    Article  PubMed  Google Scholar 

  21. Bin C, Hui W, Renyuan Z et al (2006) Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 56(4):351–357

    Article  PubMed  Google Scholar 

  22. Lagacé-Wiens PR, Nichol KA, Nicolle LE et al (2006) Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate. J Antimicrob Chemother 57(6):1262–1263

    Article  PubMed  Google Scholar 

  23. Nicolle LE, Mulvey MR (2007) Successful treatment of ctx-m ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam. Scand J Infect Dis 39(8):748–749

    Article  PubMed  CAS  Google Scholar 

  24. Rodríguez-Baño J, Alcalá JC, Cisneros JM et al (2008) Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 168(17):1897–1902

    Article  PubMed  Google Scholar 

  25. Gupta ND, Smith RE, Balakrishnan I (2009) Clinical efficacy of temocillin. J Antimicrob Chemother 64(2):431–433

    Article  PubMed  CAS  Google Scholar 

  26. Monstein HJ, Tärnberg M, Nilsson LE (2009) Molecular identification of CTX-M and blaOXY/K1 beta-lactamase genes in Enterobacteriaceae by sequencing of universal M13-sequence tagged PCR-amplicons. BMC Infect Dis 9:7

    Article  PubMed  Google Scholar 

  27. European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2010) Breakpoint tables for interpretation of MICs and zone diameters. Available online at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.1.pdf. Last date accessed 9 August 2010

  28. British Society for Antimicrobial Chemotherapy (BSAC) (2010) BSAC methods for antimicrobial susceptibility testing. Available online at: http://www.bsac.org.uk/Resources/BSAC/Version_9.1_March_2010_final.pdf. Last date accessed 2 February 2011

  29. Livermore DM, Hope R, Mushtaq S et al. (2008) Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers. Clin Microbiol Infect 14(Suppl 1):189–193

    Article  PubMed  CAS  Google Scholar 

  30. Rodriguez-Villalobos H, Malaviolle V, Frankard J et al (2006) In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 57(4):771–774

    Article  PubMed  CAS  Google Scholar 

  31. Tofteland S, Haldorsen B, Dahl KH et al (2007) Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microbiol 45(1):199–205

    Article  PubMed  CAS  Google Scholar 

  32. Liao CH, Sheng WH, Wang JT et al (2006) In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan. J Microbiol Immunol Infect 39(1):59–66

    PubMed  CAS  Google Scholar 

  33. Thomas K, Weinbren MJ, Warner M et al (2006) Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother 57(2):367–368

    Article  PubMed  CAS  Google Scholar 

  34. Livermore DM, Hope R, Fagan EJ et al (2006) Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother 57(5):1012–1014

    Article  PubMed  CAS  Google Scholar 

  35. Sorlózano A, Gutiérrez J, Romero JM et al (2007) Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli. J Basic Microbiol 47(5):413–416

    Article  PubMed  Google Scholar 

  36. Hoban DJ, Bouchillon SK, Johnson BM et al (2005) In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 52(3):215–227

    Article  PubMed  CAS  Google Scholar 

  37. Oteo J, Navarro C, Cercenado E et al (2006) Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J Clin Microbiol 44(7):2359–2366

    Article  PubMed  CAS  Google Scholar 

  38. Prakash V, Lewis JS 2nd, Herrera ML et al (2009) Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases. Antimicrob Agents Chemother 53(3):1278–1280

    Article  PubMed  CAS  Google Scholar 

  39. Colodner R, Samra Z, Keller N et al (2007) First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel. Diagn Microbiol Infect Dis 57(2):201–205

    Article  PubMed  CAS  Google Scholar 

  40. Sader HS, Hsiung A, Fritsche TR et al (2007) Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagn Microbiol Infect Dis 57(3):341–344

    Article  PubMed  CAS  Google Scholar 

  41. Gavin PJ, Suseno MT, Thomson RB Jr et al (2006) Clinical correlation of the CLSI susceptibility breakpoint for piperacillin–tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 50(6):2244–2247

    Article  PubMed  CAS  Google Scholar 

  42. Peterson LR (2008) Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin–tazobactam. Clin Microbiol Infect 14(Suppl 1):181–184

    Article  PubMed  CAS  Google Scholar 

  43. Hernández JR, Velasco C, Romero L et al (2006) Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain. Int J Antimicrob Agents 28(5):457–459

    Article  PubMed  Google Scholar 

  44. Kiremitci A, Dinleyici EC, Erben N et al (2008) In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey. Expert Opin Pharmacother 9(9):1441–1449

    Article  PubMed  CAS  Google Scholar 

Download references

Funding

This work was supported by the Medical Research Council of Southeast Sweden.

Transparency declaration

Nothing to declare.

Author contributions

MT, ÅÖB, H-JM, AH, HH, and LEN participated in the conception, design, and drafting of the manuscript, and final approval of the version to be published. MT was responsible for the laboratory work, analysis, statistical calculations, and interpretations. MT, ÅÖB, and LEN were responsible for the clinical strain collection.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Tärnberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tärnberg, M., Östholm-Balkhed, Å., Monstein, HJ. et al. In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli . Eur J Clin Microbiol Infect Dis 30, 981–987 (2011). https://doi.org/10.1007/s10096-011-1183-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-011-1183-4

Keywords

Navigation